Abstract Number: PB0144
Meeting: ISTH 2022 Congress
Theme: Diagnostics and OMICs » Biomarkers of Thrombosis and Hemostasis
Background: Despite antithrombotic therapy, many patients with coronary artery disease (CAD) suffer recurrent cardiovascular events. Hence, new biomarkers are warranted to help identify high-risk patients. MicroRNAs (miR) may influence the risk of recurrent events in CAD by regulating platelet function.
Aims: We aimed to identify candidate miRs associating with platelet function in CAD patients receiving antithrombotic monotherapy with aspirin 75 mg daily and to investigate their utility in predicting future cardiovascular events.
Methods: We identified nine candidate miRs by performing a systematic review and a pilot study comparing 40 CAD patients with 20 healthy individuals. Subsequently, we investigated the expression of the identified candidate miRs and their relation to platelet function and cardiovascular events in a cohort of 749 CAD patients. Platelet function was analysed by impedance and optical aggregometry. Patients were followed for a median of 3 years. The primary endpoint was a composite of cardiovascular death, myocardial infarction (MI), stent thrombosis (ST) and ischaemic stroke. The secondary endpoint was a composite of MI and ST. Approvals were obtained from the Committee of Health Research Ethics.
Results: The expression of miR-93, -126 and -150 correlated significantly with platelet function (p < 0.001, rho ranging from -0.13 to -0.36) in CAD patients. The combination of miR-223 expression, miR-150 expression and conventional risk factors (age, gender, body mass index, smoking, diabetes mellitus, prior myocardial infarction and creatinine) significantly increased the predictive value (AUC) of both the primary and secondary endpoint compared with clinical risk factors alone: 0.66 (0.59-0.72) vs 0.57 (0.49-0.63), p=0.01 and 0.75 (0.69-0.81) vs 0.59 (0.51-0.68), p=0.0002, respectively, Figure 1.
Conclusion(s): The expression of specific miRs may be important for platelet function and hence contribute to the risk of recurrent cardiovascular events. Adding the combination of miR-223 and miR-150 expressions to clinical cardiovascular risk factors improves risk assessment in CAD patients.
Figure 1
Figure 1. Receiver operating characteristic curves showing the best combination of microRNA expression, conventional cardiovascular risk factors and the two combined to predict cardiovascular events in patients with coronary artery disease
To cite this abstract in AMA style:
Pedersen O, Nissen P, Pasalic L, Larsen S, Kristensen S, Grove E, Hvas A. Expression of microRNAs related to platelet function and cardiovascular events in patients with stable coronary artery disease [abstract]. https://abstracts.isth.org/abstract/expression-of-micrornas-related-to-platelet-function-and-cardiovascular-events-in-patients-with-stable-coronary-artery-disease/. Accessed October 1, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/expression-of-micrornas-related-to-platelet-function-and-cardiovascular-events-in-patients-with-stable-coronary-artery-disease/